Boehringer Ingelheim announced that the transition to Combivent Respimat (ipratropium bromide and albuterol) Inhalation Spray is nearly complete. Combivent Respimat, which combines two short-acting bronchodilators, is indicated for the maintenance treatment of COPD when a second aerosol bronchodilator is needed.
Distribution of Combivent Inhalation Aerosol (MDI) will cease in May, and once stock runs out, Combivent Respimat will be the only Combivent product available.
Combivent Respimat is a propellant-free inhaler that uses a slow-moving mist to deliver the same active ingredients as Combivent MDI. Patients will require a new prescription prior to the transition from Combivent MDI to Combivent Respimat. The new formulation was developed in response to the Montreal Protocol that phased out the substances believed to be responsible for ozone depletion, including some inhalers that use chlorofluorocarbon (CFCs) propellants, such as Combivent MDI.
For more information call (800) 542-6257 or visit Combivent.com.